T Cell News and Research

Latest T Cell News and Research

New data on ZOLINZA (vorinostat) in combination with Bortezomib

Results from two Phase 1 studies of ZOLINZA (vorinostat), Merck's oral histone deacetylase (HDAC) inhibitor, administered in combination with bortezomib, showed early anti-tumor activity in patients with relapsed and/or refractory multiple myeloma, including those previously treated with and no longer responding to bortezomib.

10 Dec 2008

Lip balms, sunscreens make ideal stocking fillers, dermatologist says

If you're in need of some stocking-stuffer ideas, consider lip balms and sunscreens for your loved ones.

10 Dec 2008

Intense chemo wards off recurrence in half of mantle cell lymphoma patients after seven years

More than half of younger mantle cell lymphoma patients who received an intensive regimen of chemotherapy as frontline treatment remain in remission seven years later, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

10 Dec 2008

New discovery on cell division could improve chemotherapies for cancer

Researchers from the Ludwig Institute for Cancer Research at the University of California, San Diego School of Medicine have identified a key step required for cell division in a study that could help improve therapies to treat cancer.

10 Dec 2008

Researchers visualize three-dimensional structure of protein, Mcm10

For the first time, structural biologists have managed to obtain the detailed three-dimensional structure of one of the proteins that form the core of the complex molecular machine, called the replisome, that plant and animal cells assemble to copy their DNA as the first step in cell reproduction.

10 Dec 2008

$EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients$

EntreMed starts trial of ENMD-2076 in refractory multiple myeloma patients

EntreMed, Inc. has announced that it has initiated a Phase 1 study of ENMD-2076 in refractory multiple myeloma patients.

10 Dec 2008

New biosensor could help the search for new drugs

Chalmers researcher Andreas Dahlin has developed a biosensor with an artificial membrane, which means that membrane-bound proteins can retain their natural structure and function.

10 Dec 2008

Drug combo improves or stabilizes disease for relapsed multiple myeloma patients

Mayo Clinic researchers have found that a new combination of medications designed to maximize immune functions improved or stabilized multiple myeloma for 76 percent of patients who had relapsed after previous treatment.

10 Dec 2008

Computation and genomics data drive bacterial research into new golden age

A potent combination of powerful new analysis methods and abundant data from genomics projects is carrying microbiology forward into a new era.

10 Dec 2008

Researchers visualize how cells coordinate their movements

Using novel imaging, labeling, and data-analysis techniques, scientists from the California Institute of Technology (Caltech) have been able to visualize, for the first time, large numbers of cells moving en masse during some of the earliest stages of embryonic development.

10 Dec 2008

Protein could prevent blocked arteries

For the first time, researchers have found that a modified form of a naturally occurring protein, N-cadherin, could prevent blocked arteries. Blocked arteries are a major cause of heart attacks and strokes.

10 Dec 2008

When less is more: Brief inhibition of cancer target is effective and less toxic

New research shows that the delicate balance between maximum clinical impact and toxicity may not be quite as fragile as scientists had previously believed.

8 Dec 2008

Statins do not interfere with Rituximab treatment for lymphomas

Statins, drugs widely prescribed to lower cholesterol, do not interfere with a commonly used medication to treat lymphomas, according to a Mayo Clinic study presented at the 50th Annual Meeting of the American Society of Hematology in San Francisco.

8 Dec 2008

Researchers study virus with unusual properties

A team of researchers from Penn State University and the University of Chicago has uncovered clues that may explain how and why a particular virus, called N4, injects an unusual substance -- an RNA polymerase protein -- into an E. coli bacterial cell.

8 Dec 2008

Researchers discover why Gleevec-type drugs control, but do not eradicate leukemia

Oregon Health & Science University Knight Cancer Institute researchers are closer to understanding why certain chronic myeloid leukemia mutations are not stopped by the revolutionary targeted cancer pill, Gleevec, or similar therapies in that drug family.

8 Dec 2008

Levels of insulin-related proteins indicate risk of death in some colorectal cancer patients

A pair of proteins may help explain why people with surgically removed colorectal cancer and who are overweight, physically inactive, and follow a Western-pattern diet may have an increased risk of dying of the disease or other causes, Dana-Farber Cancer Institute scientists report in a new study.

8 Dec 2008

Nuts and Mediterranean diet appear to help metabolic syndrome

A traditional Mediterranean diet with an additional daily serving of mixed nuts appears to be useful for managing some metabolic abnormalities in older adults at high risk for heart disease, according to a report in the December 8/22 issue of Archives of Internal Medicine.

8 Dec 2008

Mathematical model shows how organelles function within cells

Cells are filled with membrane-bound organelles like the nucleus, mitochondria and endoplasmic reticula.

8 Dec 2008

Lenalidomide safe for elderly patients with chronic lymphocytic leukemia

The oral medication lenalidomide is safe and well-tolerated for elderly patients with chronic lymphocytic leukemia, a group without a well-defined frontline therapy for their disease, researchers from The University of Texas M. D. Anderson Cancer Center reported today at the 50th annual meeting of the American Society of Hematology.

8 Dec 2008

Kiadis Pharma receives two orphan drug designations for Reviroc

Kiadis Pharma has announced that the U.S. Food and Drug Administration (FDA) has granted its product Reviroc Orphan Drug Designations (ODD) for the treatment of two types of Non-Hodgkin Lymphoma (NHL).

8 Dec 2008